Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
复制标题
DOI：
10.1038/bcj.2017.47
复制
发表时间：
2017-06-16
影响因子：
12.8
通讯作者：
Dimopoulos MA
中科院分区：
文献类型：
--
作者：
Kastritis E;Gavriatopoulou M;Roussou M;Fotiou D;Ziogas DC;Migkou M;Eleutherakis-Papaiakovou E;Panagiotidis I;Kanellias N;Psimenou E;Papadopoulou E;Pamboucas C;Manios E;Gakiopoulou H;Ntalianis A;Tasidou A;Giannouli S;Terpos E;Dimopoulos MA
Bortezomib, in combination with dexamethasone (VD) or with the addition of cyclophosphamide (VCD), is highly effective in patients with amyloid light-chain (AL) amyloidosis. Currently, VCD is considered as a primary regimen for patients with AL, but it is not clear whether the addition of cyclophosphamide to VD further and significantly improves efficacy, given the substantial activity of bortezomib itself. We retrospectively compared the outcomes of 101 patients with AL amyloidosis who received VD (n=59) or VCD (n=42) in two consecutive periods. Early mortality after adjustment for Mayo stage was similar. On intent to treat, a hematologic response rate was 68% for patients treated with VD and 78% for VCD (P=0.26), while complete response+very good partial response (CR+VGPR) rate was 47.5% and 35%, respectively. Higher doses of dexamethasone or twice-weekly bortezomib were not associated with significantly higher CR+VGPR rates. Organ responses occurred in similar rates between the two groups. Median survival was similar (33 vs 36 months, P=0.45) even after adjustment for Mayo stage and dose and schedule of bortezomib and dexamethasone. In conclusion, bortezomib even with low doses of dexamethasone is effective for the treatment of AL amyloidosis; higher doses of dexamethasone and addition of cyclophosphamide do not seem to have a profound effect on efficacy and survival.
登录
查看更多内容
影响因子：
45.3
作者：
Kourelis, Taxiarchis V.;Kumar, Shaji K.;Dispenzieri, Angela
通讯作者：
Dispenzieri, Angela
影响因子：
20.3
作者：
Dispenzieri, Angela;Lacy, Martha Q.;Gertz, Morie A.
通讯作者：
Gertz, Morie A.
影响因子：
20.3
作者：
Cavo, Michele;Rajkumar, S. Vincent;Lonial, Sagar
通讯作者：
Lonial, Sagar
影响因子：
20.3
作者：
Palladini, Giovanni;Hegenbart, Ute;Schoenland, Stefan
通讯作者：
Schoenland, Stefan
影响因子：
45.3
作者：
Kastritis, Efstathios;Wechalekar, Ashutosh D.;Palladini, Giovanni
通讯作者：
Palladini, Giovanni